Xerostomia Clinical Trial
Official title:
Xerostomia in Patients With a Life-limiting Condition or Frailty: a Double-blind Placebo-controlled Randomized Clinical Trial
Xerostomia, the subjective feeling of dry mouth, is a common symptom during the last year of life in patients with a life-limiting condition or frailty. Xerostomia leads to functional alterations (such as burning sensations, an altered taste perception, and difficulties with chewing, swallowing, and speaking), has disabling social consequences and significantly downgrades the perceived quality of life. It is an under-exposed and under-treated symptom often caused by alterations in the quality and quantity of saliva. Locally administered pilocarpine could be a promising drug in this regard as it alleviates xerostomia by increasing the production of saliva.
Status | Not yet recruiting |
Enrollment | 120 |
Est. completion date | June 2025 |
Est. primary completion date | February 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - have a life-limiting condition or frailty - have the complaint dry mouth = 5 on an 11 point numerical rating scale (ranging from 0= no dry mouth to 10= worst dry mouth ever) - fulfil the single SQ 'Would I be surprised if my patient dies within the year? (no) Exclusion Criteria: - their life expectancy is less than 4 weeks (the primary endpoint at 4 weeks) - they have had radiotherapy to the salivary glands or suffer from Sjögrens disease (impact on dry mouth) - cognitively impaired to such an extent that there is insufficient understanding to complete questionnaires |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Maastricht University Medical Center | ZonMw: The Netherlands Organisation for Health Research and Development |
Theunissen M, Rideaux-Seferina S, Magdelijns FJ, Janssen DJA, van den Beuken-van Everdingen MHJ. Local Oral Pilocarpine Drops for Relieving Xerostomia (Dry Mouth) in the Elderly: A Pilot Study. J Am Med Dir Assoc. 2021 Jan;22(1):185-186. doi: 10.1016/j.jamda.2020.06.036. Epub 2020 Aug 13. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The percentage responders at week 4 of topical pilocarpine administration, as compared to baseline. | A patient counts as a responder with, at least, a 2-point reduction on the 11-point NRS | 4 weeks | |
Secondary | Mean difference in NRS dry mouth scores in the pilocarpine group at all time-points, as compared to the placebo group | Mean difference in NRS dry mouth scores is determined as mean change from baseline | 4 - 12 weeks | |
Secondary | Change in Oral Health-Related Quality of Life (OHRQoL) upon pilocarpine treatment, as compared to the placebo group | The OHRQoL is measured using the Geriatric Oral Health Assessment Index (GOHAI-NL) | 4 - 12 weeks | |
Secondary | Change in the Health-Related Quality of Life upon pilocarpine treatment, as compared to the placebo group | The HRQoL will be assessed using the EQ-5D-5L questionnaire | 4 - 12 weeks | |
Secondary | Change in clinical functioning upon pilocarpine treatment, as compared to the placebo group | Clinical functioning is determined using the Patient-reported functional status (PRFS) questionnaire | 4 - 12 weeks | |
Secondary | Change in the Global Perceived Effect (GPE) upon pilocarpine treatment, as compared to the placebo group | The GPE is determined by a globally experienced effect score | 4 - 12 weeks | |
Secondary | The durability of the effect of the use of pilocarpine on xerostomia | The durability will be displayed in percentage | 4 - 12 weeks | |
Secondary | The adherence rate of patients | Adherence will be displayed in percentage | 4 -12 weeks | |
Secondary | Possible side effects related to the intake of pilocarpine medication, as compared to the placebo group | Side effects are made transparent by providing an overview of which and how many side effects occur | 4 - 12 weeks | |
Secondary | Cost Effectiveness Analysis (CEA) of the pilocarpine treatment | The costst of patients is analysed using the medical consumption questionnaire (iMCQ) | 4 - 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05342272 -
Comparison of Gum® HydralTM Moisturizing Gel and Biotene® Oral Gel in Dry Mouth Sensation Reduction
|
Phase 3 | |
Completed |
NCT03302676 -
The Use of Chewing Gum for Xerostomia and Hyposalivation After Radiotherapy for Oral and Oropharyngeal Tumors
|
N/A | |
Completed |
NCT02375451 -
Effect of Childhood Radioiodine Therapy on Salivary Function
|
N/A | |
Completed |
NCT01272570 -
Oral Health and Oral Health-Related Quality of Life in Early Stage Breast Cancer Survivors
|
N/A | |
Completed |
NCT00656513 -
Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer
|
Phase 2/Phase 3 | |
Completed |
NCT00911768 -
Effect of Korean Red Ginseng (KRG) on Dry Mouth
|
Phase 4 | |
Completed |
NCT00332618 -
Efficacy Study of Oxygenated Glycerol Triesters to Treat Xerostomia
|
Phase 2 | |
Completed |
NCT03494985 -
A Clinical Study to Evaluate the Efficacy of Three Dry Mouth Relief Products Versus Water
|
N/A | |
Completed |
NCT05058430 -
SaliPen Human Factors Study for OTC Labeling
|
N/A | |
Recruiting |
NCT02705937 -
Early Phase Study Comparing the Effectiveness of a Dairy Product With the Reference Treatment Aequasyal® on Dry Mouth Symptoms in Patients Suffering From Xerostomia Caused by Psychotropic Medications.
|
N/A | |
Completed |
NCT05247008 -
Effectiveness of Thyme Honey in Management of Xerostomia in ESRD
|
N/A | |
Recruiting |
NCT03632096 -
Photobiomodulation in Salivary Production of Patients With Xerostomy
|
Phase 2 | |
Not yet recruiting |
NCT04323384 -
The Effect of Biotene® on the Symptoms of Xerostomia and Mastication and Swallowing
|
N/A | |
Not yet recruiting |
NCT03530735 -
Finger-prick Autologous Blood (FAB) for Use in Dry Mouth
|
N/A | |
Active, not recruiting |
NCT03176368 -
Coconut Oil: Managing Radiation-Induced Xerostomia
|
N/A | |
Enrolling by invitation |
NCT06122636 -
Efficacy of a Probiotic and Microbiological Analysis on Oral Complications Induced by Antineoplastic Therapies in Patients With HNC
|
N/A | |
Completed |
NCT03611283 -
Topical Management of Xerostomia With Dry Mouth Products
|
N/A | |
Completed |
NCT02682199 -
Prospective Evaluation of Patient Reported Xerostomia After Whole Brain Radiation
|
||
Withdrawn |
NCT01960101 -
Development of a Milk Product Substitution for Patients Suffering From Xerostomia Caused by Medication
|
N/A | |
Completed |
NCT02317172 -
Efficacy of Novel Edible Gel-based Artificial Saliva in Thai Geriatric Populations With Systemic Diseases
|
N/A |